INmune Bio Inc. (INMB) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

9/25

Growth 2 Margin 1 Expansion 3 Platform 1 Financial 2

latest quarter score

Earnings Reports

9
InMune Bio (INMB) Q2 2026: R&D Expenses Drop 86% as Regulatory Milestones De-risk Platform
August 07, 2026
7
InmuneBio (INMB) Q1 2025: Alzheimer’s Addressable Market Expands to 70% on APOE4 Biomarker Shift
May 08, 2026
7
ImmuneBio (INMB) Q4 2025: Cordstrom Heads for 2026 Regulatory Filings as R&D Spend Drops 38%
March 31, 2026
8
ImmuneBio (INMB) Q3 2025: R&D Spend Down 52% as Cordstrom and XPro Advance Toward Regulatory Milestones
October 30, 2025
8
ImmuneBio (INMB) Q2 2025: $16.5M Asset Write-Off Signals Strategic Reset on ExPro Path
August 08, 2025
9
INmune Bio (INMB) Q1 2025: Alzheimer’s Market Opportunity Expands to 70% with Imminent Phase 2 Readout
May 08, 2025
7
INmune Bio (INMB) 2024: $42M Net Loss Reflects Clinical Progress and Strategic Pivot Ahead of Alzheimer’s Data
March 27, 2025

Browse all companies